It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.

Danaher Corporation has reported impressive results for the first quarter of 2021, with earnings surpassing estimates by 50.9%. Also, the company’s sales surpassed the Zacks Consensus Estimate by 0.6%.

A biochemistry analyzer is an instrument that automatically completes the steps of sampling, adding reagents, removing interfering substances, mixing, constant temperature reaction, automatic monitoring, data processing, post-cleaning, etc.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

A team led by researchers at the University of Michigan has developed and clinically validated an 18-gene urinary test for detecting high-grade prostate cancer.

BGI Genomics, a global leader in integrated precision medicine solutions, has established a new clinical laboratory at Uruguay's Parque de las Ciencias free trade zone. This facility is poised to become a regional hub, advancing preventive medicine across Latin America and utilizing advanced technology to facilitate early disease diagnosis.

The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen.

NanoString Technologies said on Wednesday after the close of the market that Bruker will acquire substantially all of its assets for approximately $392.6 million in cash. In addition, Bruker will assume certain liabilities from NanoString.

Abbott on Wednesday announced that its Q1 2024 Diagnostics revenues declined 18 percent year over year as a result of declining COVID-19 testing sales.

In April, the recent release of the 2024 medical device classification encompasses 223 results, including 93 products related to In Vitro Diagnostics (IVD). Among these, 27 IVD-related products are suggested for Class III medical device management, 45 for Class II, and 14 for Class I.